Universal Heparin Reversal Agents for Antithrombotic Therapy
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current antithrombotic drugs, such as heparin, have significant toxicity and risk of bleeding events due to their interaction with proteins and cell surfaces, limiting their clinical usefulness in inhibiting thrombosis effectively.
Innovation Solution
Development of low molecular weight, high charge density Universal Heparin Reversal Agents (UHRAs) that selectively inhibit polyphosphate (polyP) pro-coagulant activity, reducing bleeding risks and toxicity by binding specifically to polyP, thereby acting as antithrombotic agents with a hydrophilic polymeric outer shell.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If cationic polymers (PEI, PAMAM dendrimers) are used to inhibit polyP, then polyP binding affinity is improved, but cellular toxicity and platelet activation increase
Solution Approach 1:
The patent applies local quality by creating a polymer with heterogeneous structure: cationic polyP-binding groups are localized at specific sites to provide high polyP affinity, while the bulk of the polymer chain consists of neutral or hydrophilic groups that reduce non-specific binding to proteins and cell surfaces. This spatial differentiation of functional groups resolves the contradiction between high polyP binding and low cellular toxicity.
Solution Approach 2:
The patent changes key parameters of the polymer structure: using lower molecular weight (reducing overall polymer mass that causes toxicity), optimizing charge density (providing sufficient cationic groups for polyP binding without excessive positive charge that causes non-specific binding), and adjusting the ratio of cationic to neutral groups. These parameter optimizations simultaneously achieve high polyP affinity and reduced cellular toxicity.
2Reliability
If cationic polymers are used to inhibit polyP, then thrombosis inhibition is improved, but bleeding risk increases due to fibrinogen aggregation
Solution Approach 1:
The patent applies local quality by concentrating cationic polyP-binding groups at specific localized sites on the polymer structure, while the remainder of the polymer consists of neutral hydrophilic groups. This localized functionality provides sufficient thrombosis inhibition through polyP binding without the excessive non-specific protein binding that causes fibrinogen aggregation and increased bleeding risk.
Solution Approach 2:
The patent optimizes critical parameters including charge density (balancing sufficient positive charge for polyP binding with reduced non-specific binding), molecular weight (using lower molecular weight polymers that provide adequate polyP inhibition with reduced fibrinogen interaction), and hydrophilicity (increasing hydrophilic character to reduce protein aggregation). These parameter changes simultaneously achieve thrombosis inhibition while reducing bleeding risk.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
UHRAs effectively inhibit polyP pro-coagulant activity in vitro and in vivo, reducing arterial thrombosis and bleeding risks compared to heparin, offering a novel platform for antithrombotic therapy with reduced side effects.
Implementation Method 1
Both of these types of polymers are positively charged due the presence of multiple primary amines, which allows them to bind to and inhibit polyP
Implementation Method 2
with an outer shell which is a hydrophilic polymeric system
Data Source
AI summary
Provided herein are polymers and methods for their use in binding a phosphate containing biological macromolecules. Specifically, the methods and uses provided herein may be used to inhibit thrombin binding to polyphosphate or as an antithrombotic agent for the treatment of stroke, acute coronary syndrome, pulmonary embolism, atrial fibrillation, venous and arterial thromboembolism, disseminated intravascular coagulation (DIC), deepvein thrombosis (DVT), peripheral artery disease, trauma-induced coagulopathy, extracorporeal circulation, cancer-associated thrombosis, sepsis, septic shock, Systemic Inflammatory Response Syndrome (SIRS), or inflammation.